Royal Prima Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Royal Prima Tbk. trades at Rp120 (market cap 397.03B, 3.81M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Royal Prima Tbk. is far larger — about 3.8× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| PRIM | SCPI | |
|---|---|---|
Market Cap | 397.03B | 104.4B |
Volume | 3.81M | — |
Lot | 38.09K | — |
Turnover | 449.6M | — |
Average Price | 118.04 | — |
Value | 449.6M | — |
Indicative Equilibrium Price | 120 | — |
Indicative Equilibrium Volume | 1 | — |
Trailing returns across standard periods
Latest headlines on both assets
PT Royal Prima (the Company) was established based on notarial deed No. 1 dated 4 June 2013 of Heriyanti, S.H., M.Kn., notary in Medan.
Read more on PRIM →PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →